Skip to content

Protected: Studies

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with a 52 Week Blinde

Calendar Name Roche
Description The following MRI sequences will be acquired at each patient visit: 2 Scouts: • Fast Localizer (3 Plane) • True mid-line sagittal 7 Sequences: • 3D sagittal T1 Global • Resting state fMRI (+B0
PI Tanya Simuni
People Cynthia Poon
Business Administrator -
Resources 3T Trio (Neuro)
IRB STU00205125
Start Date 2017-09-18
End Date 2019-12-31
Chart String 640-5210500-60047830
Affiliates No